Equibles does not estimate personal net worth.
Get an email with a short summary when Biomarin Pharmaceutical Inc publishes a filing, an earnings call transcript or a press release.
Get BMRN alertsBiomarin Pharmaceutical Inc reported in an 8-K filed August 22, 2024 that Greg Friberg was appointed Executive Vice President, Chief Worldwide Research and Development Officer, effective September 30, 2024. Greg Friberg has spoken on 4 earnings calls and 1 other investor event across 1 company, most recently for Biomarin Pharmaceutical Inc on November 2, 2026. Biomarin Pharmaceutical Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Biomarin Pharmaceutical Inc includes Alexander Hardy (CEO and Board Member), Richard A. Meier (Chairman), Brian Mueller (CFO) and 7 others.
“He will continue in his current role until Dr. Greg Friberg assumes the position of Executive Vice President, Chief Worldwide Research and Development Officer, which is expected on September 30, 2024.”
“Turning to slide 11, we are quite pleased to have four new assets under development, having leveraged externally sourced innovation to add multiple new programs to our pipeline this year.”
“It's fantastic to be able to talk a bit about Biomarin's research and development. We are in the process of building out our pipeline, but there are a couple of highlights I want to share for you.”
“We have a very busy year ahead for R&D with multiple meaningful milestones. Moving to slide 14, as Kristen mentioned, we are preparing to submit the full approval package for Voxogo and achondroplasia.”
“As Alexander mentioned, we recently completed enrollment in our pivotal study for Voxogo in hypochondroplasia. We will be sharing the 52-week results next year and will be seeking an approval for 2027 should the data be supportive.”
“Starting with BMN-333, recall that in non-human primates, we achieved sustained pre-CNP exposures several-fold higher than those demonstrated for other long-acting CNP agents.”
2024-09-30–present
Biotechnology · Healthcare
